Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells $15,500.00 in Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of Century Therapeutics stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $3.10, for a total transaction of $15,500.00. Following the completion of the sale, the insider now owns 297,319 shares in the company, valued at approximately $921,688.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Century Therapeutics Trading Down 5.4 %

Shares of NASDAQ IPSC traded down $0.17 during mid-day trading on Wednesday, reaching $2.96. The company had a trading volume of 134,089 shares, compared to its average volume of 199,775. Century Therapeutics, Inc. has a 52-week low of $1.28 and a 52-week high of $5.51. The firm has a 50 day simple moving average of $4.13 and a two-hundred day simple moving average of $3.13.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.07. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.69 million. On average, sell-side analysts expect that Century Therapeutics, Inc. will post -1.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

IPSC has been the topic of a number of analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $9.00 target price (down from $10.00) on shares of Century Therapeutics in a research note on Friday, April 12th. Canaccord Genuity Group lifted their target price on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Century Therapeutics in a report on Friday, March 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Century Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $13.60.

Institutional Trading of Century Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IPSC. Avidity Partners Management LP lifted its stake in shares of Century Therapeutics by 23.4% in the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after purchasing an additional 256,500 shares during the period. Abel Hall LLC acquired a new position in Century Therapeutics during the fourth quarter worth about $33,000. Finally, Federated Hermes Inc. raised its position in Century Therapeutics by 0.4% during the fourth quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.